Acadia Pharmaceuticals price target raised to $19 from $15 at Mizuho

Mizuho analyst Uy Ear raised the firm’s price target on Acadia Pharmaceuticals to $19 from $15 and keeps a Neutral rating on the shares. The company reported "solid" Q4 Nuplazid sales and provided first-time 2023 Nuplazid sales guidance of $520M-550M that missed the consensus of $551M, the analyst tells investors in a research note. The analyst believes the potential for Nuplazid guidance to miss is widely-known among buy-siders, however, and wouldn’t expect much of a stock reaction from the shortfall.